The Project with F.Hoffmann-La Roche Ltd
In 2011, the world’s leading manufacturer of pharmaceuticals, the F.Hoffmann-La Roche Ltd Company, and the domestic company Lumier Pharma implemented a mutual social project aimed at improving the accessibility of medications and the quality of medicines, as well as optimizing treatment results in patients with viral hepatitis diseases and HIV/AIDS with co-infection.
In the framework of this project, PEGASIS, PEG-interferon alfa-2а, injection solution, 180 mcg/1 ml in vials is produced; the medicine is registered in Ukraine under the name of PEGFERON.
In Ukraine, the situation with viral hepatitis B and C among the population is very complicated; in terms of viral hepatitis C expansion tempo, Ukraine ranks one of the highest in Europe. Viral hepatitis diseases perform negative impact on the population’s health condition; gradual progressing of chronic viral hepatitis diseases causes the development of liver cirrhosis and cancer, disability, and, as a result, reduces life expectancy.
Today, the “golden standard” of antivirus treatment of chronic viral hepatitis both in Ukraine and worldwide is combined therapy of pegylated interferon-alpha and ribavirin.
PEGFERON, PEG-interferon alfa-2а is the first local pegylated interferon designated for the treatment of patients with viral hepatitis and HIV/AIDS with co-infection that demonstrates effectiveness clinically proven both in Ukraine and abroad.